Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 10 (14) , 3259-3266
Abstract
Objective: To explore whether cultured CTC from bladder-cancer patients originate from bladder cancer and share chromosomal abnormalities, by means of a fluorescence in situ hybridization (FISH) test.Keywords
This publication has 29 references indexed in Scilit:
- Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic CancersEuropean Urology, 2018
- Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture deviceNature Protocols, 2017
- Cancer gene panel analysis of cultured circulating tumor cells and primary tumor tissue from patients with breast cancerOncology Letters, 2017
- Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLCFrontiers in Oncology, 2014
- Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chipLab on a Chip, 2013
- Evaluation of urovysion and cytology for bladder cancer detectionCancer Cytopathology, 2013
- The Evolving War on CancerCell, 2011
- Bladder Cancer Detection Using FISH (UroVysion Assay)Advances in Anatomic Pathology, 2008
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsNew England Journal of Medicine, 2008
- Multitarget Fluorescence In Situ Hybridization Assay Detects Transitional Cell Carcinoma in the Majority of Patients with Bladder Cancer and Atypical or Negative Urine CytologyJournal of Urology, 2003